© 2003 by Oxford University Press
© 2003 Oxford University Press
REVIEW |
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
Affiliations of authors: H. Choy, Vanderbilt-Ingram Cancer Center, Nashville, TN; L. Milas, University of Texas M.D. Anderson Cancer Center, Houston, TX.
Correspondence to: Hak Choy, MD, Department of Radiation Oncology, Vanderbilt University Medical Center, 1301 22nd Ave. South, Nashville, TN 37232–5671 (e-mail: hak.choy{at}utsouthwestern.edu).
Results of preclinical studies suggesting that the efficacy of molecular therapies is enhanced when they are combined with radiation have generated a surge of clinical trials combining these modalities. We reviewed the literature to identify the rationale and experimental foundation supporting the use of cyclooxygenase-2 (COX-2) inhibitors with standard radiotherapy regimens in current clinical trials. Radiation affects the ability of cells to divide and proliferate and induces the expression of genes involved in signaling pathways that promote cell survival or trigger cell death. Future advances in radiotherapy will hinge on understanding mechanisms by which radiation-induced transcription of genes governs cell death and survival, the selective control of this process, and the optimal approaches to combining this knowledge with existing therapeutic modalities. COX-2 is expressed in all stages of cancer, and in several cancers its overexpression is associated with poor prognosis. Evidence from clinical and preclinical studies indicates that COX-2–derived prostaglandins participate in carcinogenesis, inflammation, immune response suppression, apoptosis inhibition, angiogenesis, and tumor cell invasion and metastasis. Clinical trial results have demonstrated that selective inhibition of COX-2 can alter the development and the progression of cancer. In animal models, selective inhibition of COX-2 activity is associated with the enhanced radiation sensitivity of tumors without appreciably increasing the effects of radiation on normal tissue, and preclinical evidence suggests that the principal mechanism of radiation potentiation through selective COX-2 inhibition is the direct increase in cellular radiation sensitivity and the direct inhibition of tumor neovascularization. Results of current early-phase studies of non–small-cell lung, esophageal, cervical, and brain cancers will determine whether therapies that combine COX-2 inhibitors and radiation will enter randomized clinical trials.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. K. Sackett, I. Bairati, F. Meyer, E. Jobin, S. Lussier, A. Fortin, M. Gelinas, A. Nabid, F. Brochet, and B. Tetu Prognostic Significance of Cyclooxygenase-2 Overexpression in Glottic Cancer Clin. Cancer Res., January 1, 2008; 14(1): 67 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. He, T. A. Luster, and P. E. Thorpe Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids Clin. Cancer Res., September 1, 2007; 13(17): 5211 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. de Heer, M. J.E.M. Gosens, E. C. de Bruin, N. G. Dekker-Ensink, H. Putter, C. A.M. Marijnen, A. J.C. van den Brule, J. H. J.M. van Krieken, H. J.T. Rutten, P. J.K. Kuppen, et al. Cyclooxygenase 2 Expression in Rectal Cancer Is of Prognostic Significance in Patients Receiving Preoperative Radiotherapy Clin. Cancer Res., May 15, 2007; 13(10): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy. Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zijlstra, M. Seandel, T. A. Kupriyanova, J. J. Partridge, M. A. Madsen, E. A. Hahn-Dantona, J. P. Quigley, and E. I. Deryugina Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells Blood, January 1, 2006; 107(1): 317 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Palayoor, M. J. Arayankalayil, A. Shoaibi, and C. N. Coleman Radiation Sensitivity of Human Carcinoma Cells Transfected with Small Interfering RNA Targeted against Cyclooxygenase-2 Clin. Cancer Res., October 1, 2005; 11(19): 6980 - 6986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Crokart, K. Radermacher, B. F. Jordan, C. Baudelet, G. O. Cron, V. Gregoire, N. Beghein, C. Bouzin, O. Feron, and B. Gallez Tumor Radiosensitization by Antiinflammatory Drugs: Evidence for a New Mechanism Involving the Oxygen Effect Cancer Res., September 1, 2005; 65(17): 7911 - 7916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Kang, E. Lee, H. Pyo, and S.-J. Lim Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells Mol. Cancer Ther., September 1, 2005; 4(9): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|